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Abstract: The GBA2 gene encodes the non-lysosomal glucosylceramidase (NLGase), an enzyme
that catalyzes the conversion of glucosylceramide (GlcCer) to ceramide and glucose. Mutations
in GBA2 have been associated with the development of neurological disorders such as autosomal
recessive cerebellar ataxia, hereditary spastic paraplegia, and Marinesco-Sjogren-Like Syndrome.
Our group has previously identified the GBA2 c.1780G>C [p.Asp594His] missense mutation, in a
Cypriot consanguineous family with spastic ataxia. In this study, we carried out a biochemical
characterization of lymphoblastoid cell lines (LCLs) derived from three patients of this family.
We found that the mutation strongly reduce NLGase activity both intracellularly and at the plasma
membrane level. Additionally, we observed a two-fold increase of GlcCer content in LCLs derived
from patients compared to controls, with the C16 lipid being the most abundant GlcCer species.
Moreover, we showed that there is an apparent compensatory effect between NLGase and the
lysosomal glucosylceramidase (GCase), since we found that the activity of GCase was three-fold
higher in LCLs derived from patients compared to controls. We conclude that the c.1780G>C mutation
results in NLGase loss of function with abolishment of the enzymatic activity and accumulation of
GlcCer accompanied by a compensatory increase in GCase.
Keywords: GBA2; non-lysosomal β-glucosylceramidase; β-glucocerebrosidase; spastic ataxia;
glucosylceramide; plasma membrane; lymphoblastoid cell lines
Int. J. Mol. Sci. 2018, 19, 3099; doi:10.3390/ijms19103099 www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2018, 19, 3099 2 of 12
1. Introduction
Sphingolipids (SLs) are a class of lipids mainly associated with the external leaflet of the plasma
membrane (PM) of all eukaryotic cells, playing an important role in the structural integrity of the
PM and cellular signaling [1]. Glycosphingolipids (GSLs) are SLs with a head-group formed by a
mono- or oligosaccharide moiety. Glucosylceramide (GlcCer) is the simplest member of GSLs and it is
formed in the Golgi complex by the glycosylation of ceramide [2]. SLs play a fundamental role in cell
physiology and this can be demonstrated by the numerous genetic diseases that arise from mutations
in enzymes involved in SL metabolism and transport [3,4]. Cells can alter their lipid composition by the
action of different hydrolases that are active at the lysosomes or at the PM, such as sphingomyelinase
(SMase), β-hexosaminidase (β-Hex), β-galactosidase (β-gal), β-glucocerebrosidase (GCase), and the
non-lysosomal β-glucosylceramidase (NLGase) [5,6].
GCase and NLGase are both involved in the catabolism of GlcCer to ceramide and glucose. GCase
(EC 3.2.1.45) is encoded by the GBA gene (MIM_606463), located on chromosome 1q21. GCase is a
membrane glycoprotein of 497 amino acids with a β-barrel structure, ubiquitously expressed in all
tissues and mainly localized in lysosomes. The catalytic site of GCase contains two highly conserved
residues of glutamic acid, which are necessary for the two-step mechanism of action, the nucleophilic
attack, and the subsequent protonation. Loss of function mutations in the GBA gene cause Gaucher
disease, the most common lysosomal storage disorder [7,8].
NLGase (EC 3.2.1.45) is encoded by the GBA2 gene localized on chromosome 9p13.3. The catalytic
site of the protein is characterized by both nucleophile and acid/base residues, Glu-528 and Asp-678
respectively. These residues define NLGase as a retaining β-glucosidase belonging to the CAZy
glycosyl hydrolase family 116 (GH116) [9]. As previously described, the retaining β-glucosidases
utilize a double-displacement mechanism [10]. In the first step of the reaction, called glycosylation, the
nucleophile residue attacks the glucose anomeric center to create the glycosyl-enzyme intermediate,
whereas the acid/base residue protonates the glycosydic oxygen, leading to the release of a glycone [11].
In the second step, the group working as an acid in the first step acts as a base catalyst that together
with incoming water determines the de-glycosylation of the nucleophile. This mechanism allows the
retention of the configuration at the anomeric carbon of the released glucose molecule [12].
The intracellular localization of NLGase has been controversial. It was reported to be a single pass
transmembrane protein [13] and later was identified as a cytoplasmic membrane-associated protein of
the ER and Golgi complex [14]. The activity of NLGase at the PM is directly modulated by the efflux of
protons through the proton pumps associated with the cell surface [15,16].
The pathological involvement of NLGase was initially studied by generating GBA2-knockout
mice [17]. Knockout mice present impairment in liver regeneration [18], and male infertility due to
GlcCer accumulation. This accumulation causes dysregulation of lipid homeostasis due to a more
ordered lipid composition of the PM [19,20]. As a result, the cytoskeletal dynamics are altered and the
formation of sperm-head shaping and acrosome is affected [19].
Despite the abnormal GlcCer accumulation in brain, GBA2-knockout mice do not display any
neurological symptoms or defects [19]. On the contrary, GBA2-knockdown zebrafish show abnormal
motor neuron development [21], and mutations in the human GBA2 gene have been found to lead to
neurological disorders like spastic ataxia (SA) [22,23], hereditary spastic paraplegia (HSP) [21,24,25],
and more recently Marinesco-Sjogren-Like Syndrome [26]. The molecular mechanism(s) leading to
the development of disease are not currently known. Only one mutation of GBA2 has been so far
functionally characterized in vivo (i.e., zebrafish model) [21]. A more detailed biochemical analysis of
the different mutants of GBA2 in patient derived cells is still missing.
We have previously identified a GBA2 missense mutation [c.1780G>C (p.Asp594His)] in a Cypriot
family with progressive spastic ataxia [22]. In vitro characterization of this mutation in COS7 and
HeLa cells showed that it causes a reduction at both the protein and enzyme activity levels [25]. In the
present study we have undertaken the biochemical characterization of the GBA2 c.1780G>C missense
mutation in lymphoblastoid cell lines (LCLs) derived from spastic ataxia patients homozygous for the
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mutation. Our results contribute to the understanding of the biochemical consequences of mutations
in the GBA2 gene.
2. Results
2.1. The c.1780G>C Mutation Results in NLGase Loss of Activity and GlcCer Accumulation
GBA2 mRNA expression levels were measured in LCLs obtained from four healthy individuals
and from three patients homozygous for the c.1780G>C mutation. As shown in Figure 1-panel A,
the same level of GBA2 transcript was found in control and patient LCLs, suggesting that the mutation
does not affect the GBA2 mRNA expression and stability.
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Figure 1. GBA2 mRNA expression and non-lysosomal glucosylceramidase (NLGase) activity. (A) The
graph represents the GBA2 mRNA levels of controls (light grey) and patients (dark grey) relative
to the average value of c trols (n = 4) after normalization with the endoge ous β-actin gene
(ACTB). Values represent the mean ± SEM of two independent triplicate experiment . (B) NLGase
activity associated with he total cell lysates and plasm membrane (PM) of controls (light grey) and
patients (dark grey) derived lymphoblastoid cell lines (LCLs). Enzymatic activity was expressed as
pmoles/106 cells/h. Data are expressed as mean ± SD of three independent triplicate experiments
(*** p < 0.0001 vs. controls).
Subsequently, we measured the NLGase enzymatic activity on the total cell lysate of the same LCLs.
We observed that NLGase activity was almost undetectable in patients’ cells with respect to controls
(Figure 1B), which are characterized by an average specific activity of 78 ± 19 pmoles/106 cells/h.
In several cell lines of different origin, NLGase was found to be associated with the external leaflet
of the PM where it catalyzes the in situ hydrolysis of glucosylceramide (GlcCer) to ceramide [27–29].
For this reason, we measured the enzymatic activity of NLGase directly at the cell surface of control
and patient derived lymphoblastoid living cells. In patients’ cells NLGase activity was also strongly
reduced at the cell surface, showing 2–4% of residual activity with respect to that found in controls
(Figure 1B; controls 44 ± 8 pmoles/106 cells/h, patients 2.3 ± 0.5 pmoles/106 cells/h). We can exclude
that the enzymatic activity measured at the PM was due to other β-glucocerebrosidases because,
by adding AMP-DNM, a specific inhibitor of NLGase to the assay solution abolished the enzymatic
activity at the cell surface. Our data demonstrate that the presence of the homozygous GBA2 c.1780G>C
mutation results in an important loss of NLGase activity.
Furthermore, we assessed the effect of the NLGase loss of function on the GlcCer content. To this
purpose, total lipid extracts obtained from the same LCLs used for the evaluation of the enzymatic
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activity were subjected to SFC-MS/MS analysis. This method is capable of quantifying and also
distinguishing GlcCer from galactosylceramide (GalCer).
As shown in Table 1, patient derived LCLs are characterized by a two-fold increase in the GlcCer
content with respect to controls. No differences were found among controls and cells expressing the
mutated protein in the level of GalCer. Moreover, no difference was found in cellular cholesterol
content between patients and controls, suggesting that GBA2 loss-of-function does not affect cholesterol
homeostasis. In Gaucher disease, where we have GCase loss-of-function, the accumulated GlcCer
is converted to glucosphingosine (GlcShp) by the action of the acid ceramidase [30]. We therefore
also analyzed the levels of GlcShp by SFC-MS/MS and these were found to be hardly detectable,
without any significant difference between control and patient cells.
Table 1. Hexosylceramides of lymphoblastoid cell lines (LCLs) from controls and patients.
Glucosylceramide (GlcCer) and galactosylceramide (GalCer) contents were evaluated by SFC-MS/MS
in controls (WT, n = 4) and patients (c.1780G>C, n = 3) LCLs. Data are expressed as pmoles/mg of cell
protein ± Error (n = 3).
Hexosylceramides of LCLs from Controls and Patients (Pmoles/mg Cell Proteins)
WT c.1780 G>C
Glucosylceramide 1080 ± 107 2009 ± 114
Galactosylceramide 9 ± 3 6 ± 2
Quantitative analysis of the different molecular species of GlcCer showed that C16 is the most
abundant species in both control and patient derived LCLs. In addition, it emerged that all the
molecular species are doubled in pathological cells with respect to controls (Table 2).
Table 2. SFC-MS/MS analysis of glucosylceramide (GlcCer) molecular species in control (WT, n = 4)
and patient (c.1780G>C, n = 3) derived LCLs. Data are the mean of three independent experiments and
are expressed as pmoles/mg of cell proteins ± SEM.
Glucosylceramide Molecular Species of LCLs from Controls and Patients (Pmoles/mg Cell Proteins)
C14 C16 C18 C18:1 C20 C22 C22:1 C24 C24:1 C26 C26:1
GlcCer
WT 13 ± 2 611 ± 100 24 ± 5 1 ± 0.1 28 ± 7 76 ± 14 6 ± 1 143 ± 22 150 ± 21 9 ± 1 15 ± 2
c.1780 G>C 21 ± 1 1139 ± 103 51 ± 2 1.3 ± 0.2 63 ± 7 145±7 11 ± 1 261 ± 20 278 ± 44 15 ± 2 21 ± 1
In order to show that the increase of GlcCer was the result of an impairment of its
catabolism, we labeled the cell sphingolipids at steady state using radioactive sphingosine [1-3H]Sph.
This experimental procedure is based on the recycling of the radioactive precursor [1-3H]Sph that is
used by the anabolic pathways as the endogenous counterpart. When there is an impairment of a
catabolic enzyme (i.e., NLGase), the [1-3H]Sph is not further recycled and no degraded radioactive
sphingolipid accumulates. As shown in Figure 2, despite the inter-individual variability in the content
of lactosylceramide (LacCer) and globotriaosylceramide (Gb3), no significant differences were found
between controls and patients for the other sphingolipids characteristic of LCLs. The only exception
was the GlcCer and the ganglioside GM3 content. All patient derived LCLs showed an increase of
more than two-fold of radioactive GlcCer with respect to control LCLs as well as a decrease of the
radioactive GM3. The reduction in patient LCLs of the ganglioside GM3, which is a lipid typically
associated with the external leaflet of the cell PM, with the concomitant increase in GlcCer, supports
the hypothesis that the impairment of the catabolic pathway occurs at the cell PM level.
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2.2. GCase Activity is Up-Regulated in GBA2-Deficient LCLs Particularly at the PM
Sever l lines evidence suggest the exis ence of a cross-talk among the enzymes involved in
sphingolipid (SL) catabolism, since modification in the activity/expression of one enzyme could
affect that of others [31]. Besides NLGase, another important enzyme involved in GlcCer catabolism
is β-glucocerebrosidase (GCase) encoded by the GBA gene. Unlike NLGase, GCase is mainly a
lysosomal enzyme and only partially associated with the external leaflet of the PM [15]. To investigate
the possibility of a cross-talk between GCase and NLGase, we measured the activity of GCase
both intracellularly and at the cell surface in control and patient derived LCLs. As shown in
Figure 3–panel A, GCase activity was increased in total cell lysates derived from patients’ cells
with respect to controls. The average activity of GCase was 102 ± 14 pmoles/106 cells/h and 71
± 17 pmoles/106 cells/h in patient and control derived LCLs, respectively. A marked increase,
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about three-fold, of GCase activity was also observed at the PM level in patients compared to
control LCLs (patients: 33 ± 9 pmoles/106 cells/h; control: 11 ± 4 pmoles/106 cells/h). Interestingly,
the augmented enzymatic activity is associated with an increase in the GCase protein levels but not in
GBA mRNA expression (Figure 3B,C).
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A substantial body of evidence shows the presence and action of mature and active lysosomal
enzymes at the PM in addition to the lysosomes [15,32]. We decided to investigate the activity of two
main hydrolases involved in SL catabolism, β-galactosidase and β-hexosaminidase, both intracellularly
and at the PM level. We observed an increase only of the β-galactosidase activity associated with the
cell surface of LCLs obtained from patients with respect to controls (Table 3).
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Table 3. Enzymatic activities associated with total cell lysate and the plasma membrane (PM) of control
(WT) and patient (c.1780 G>C) derived LCLs. Enzymatic activities were expressed as pmoles/106
cells/h ± error.
Enzymes Cell Lysate PM
WT c.1780 G>C WT c.1780 G>C
β-Galactosidase 1284 ± 246 1399 ± 149 14 ± 4 30 ± 4
β-Hexosaminidase 1868 ± 233 1961 ± 206 24 ± 6 35 ± 15
3. Discussion
Several lines of evidence indicate that the regulation of GlcCer levels is important for cell
homeostasis. GlcCer is a minor component of almost all membranes of eukaryotic cells suggesting an
evolutionary strategy aimed to limit its presence. Indeed, de novo biosynthesized GlcCer is mainly
used as a building block for the biosynthesis of complex GSLs [33].
In mammalian cells, GSL catabolism occurs by the sequential hydrolysis of the saccharidic chain
by removing the reducing sugar. Lysosomes are involved in the catabolism of the endocytic portion of
the cell PM and could be considered the principal site, together with the endoplasmic reticulum and
Golgi complex, responsible for GSLs turnover [34]. On the other hand, the fine tuning of the GSLs
composition is triggered directly at the cell PM by the action of specific glycohydrolases. In particular,
the same enzymes that are associated with the lysosomes, such as sialidase Neu1, beta-hexosaminidase,
beta-galactosiadase, and GCase, are present at the cell surface, even if in very small amounts, along with
the sialidase Neu3 and NLGase, which are enzymes primarily residing at the PM [5]. Loss of function
mutations in the lysosomal glycohydrolases determine the onset of lysosomal storage disorders,
characterized by the accumulation of non-catabolized substrates.
NLGase is currently the most studied enzyme among the PM glycohydrolases. NLGase deficient
mice, obtained both, by gene knockout and by pharmacological inhibition of the enzyme, showed an
abnormal GlcCer accumulation in multiple tissues, including brain, liver, and testis. These data
were quite surprising considering that the large amount of the GSL catabolism occurs in lysosomes.
In addition, these mice were characterized by impaired liver regeneration and male infertility but
no neurological involvement was observed [17–19]. However, in humans GBA2 gene mutations are
found in spastic ataxia and spastic paraplegia patients (SPastic Gait locus #46, SPG46) [23–25,35].
Among them, a c.1780G>C (p.Asp594His) missense mutation located in exon 11 of the GBA2 gene was
identified in a Cypriot consanguineous spastic ataxia family [22].
We used LCLs obtained from three patients of this family, who are homozygous for the GBA2
c.1780G>C missense mutation, to evaluate the effect of the mutation on NLGase activity. By an in vitro
enzymatic assay based on the use of CBE to block GCase activity, we found that the mutation strongly
affects NLGase activity. Indeed, in pathological cells we were not able to detect any NLGase activity in
the total cell lysate, and only a very low residual activity at the cell surface when compared with LCLs
derived from four healthy controls. Similar to the results observed in mice, we found that the NLGase
loss of function in patient derived LCLs is responsible for an increase of GlcCer content that reaches
two-fold to that found in control cells. In addition, patient LCLs show an increased activity of GCase
with respect to that measured in controls. In particular, GCase activity associated with the PM of patient
derived LCLs is three-fold higher than that of control LCLs. This presumably compensatory effect has
already been described in fibroblasts derived from patients affected by Gaucher disease, where the
GCase loss of function induced an increase in NLGase activity [31]. Indeed, by the evaluation of the
total cell β-glucocerebrosidase activity we did not find statistically significant differences between
control and patient derived LCLs (Figure S1).
Taken together, the data, herein reported, further support an important role of NLGase in GlcCer
metabolism and the existence of a cross-talk among the enzymes involved in GSL catabolism. Despite this
new evidence, the challenges for future studies remain: (i) to explain why NLGase loss of function with
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concomitant increase of GCase could result in GlcCer accumulation and (ii) which are the molecular
mechanisms linking the NLGase-dependent GlcCer accumulation with the onset of spastic ataxia.
4. Materials and Methods
4.1. Cell Culture
Seven LCLs (3 patients and 4 controls) were available, which were expanded and sub-cultured
for the purposes of this study. Cells were grown in culture medium RPMI (Roswell Park Memorial
Institute medium) supplemented with 10% FBS (fetal bovine serum), 1% penicillin/streptomycin and
1% glutamine, and expanded for a period of 6 weeks at 37 ◦C in a 5% CO2 incubator. Genotypes of
all patient derived LCLs sub-cultures were reconfirmed with Sanger sequencing and healthy controls
were confirmed as homozygous wild-type.
All subjects gave their informed consent for inclusion before they participated in the study.
The study was conducted in accordance with the Declaration of Helsinki, and approved by the
National Bioethics Committee of Cyprus (EEBK/EΠ/2013/28, date of approval 14 May 2015).
4.2. Evaluation of Enzymatic Activities in Cell Lysates
The enzymatic activities associated with total cell lysates were determined by an assay based
on the use of fluorogenic substrates as previously described [36]. To evaluate NLGase activity, cell
lysates were pre-incubated for 30 min at room temperature in McIlvaine buffer (pH 6) with 1 mM
CBE (Conduritol-B-epoxide, Merck, Darmstadt, Germany), a specific inhibitor of GCase [37]. For the
measurement of GCase activity, cell lysates were pre-incubated for 30 min at room temperature
in McIlvaine buffer (pH 5.2) containing 0.1% Triton X100(Merck, Darmstadt, Germany) with 5 nM
AMP-dNM (adamantane-pentyl-dNM; N-(5-adamantane-1-yl-methoxy-pentyl) deoxynojirimycin,
(A generous gift from Prof. Aerts JM form Leiden University) a specific inhibitor of NLGase.
The total β-glucocerebrosidase assay was performed using the same procedure without inhibitors
and detergents. At the end of the pre-incubation, the reactions were started by the addition of
25 µL of 4-Methylumbelliferyl β-D-glucopyranoside (MUB-β-Glc, Glycosynth, Warrington, UK)
at a final concentration of 6 mM. To measure β-galactosidase and β-hexosaminidase activities,
the fluorogenic substrates used were 4-Methylumbelliferyl β-D-galactopyranoside (MUB-β-Gal)
and 4-Methylumbelliferyl N-acetyl-β-D-glucuronide (MUG) (all from Glycosynth, Warrington, UK),
respectively. Aliquots of cell lysates were incubated with 25 µL of McIlvaine buffer 4× (0.4 M citric
acid /0.8 M Na2HPO4) pH 5.2 and the specific fluorogenic substrates at a final concentration of 500 µM.
Water was added to reach the final volumes of 100 µL. At different time points the reaction was stopped
by adding 9 volumes of 0.25 M glycine pH 10.7 (Sigma-Aldrich, St. Louis, MO, USA). The fluorescence
was detected by a Victor microplate reader (Perkin Elmer, Waltham, MA, USA). Standards of free
4-methylumbelliferone (MUB) were used to construct calibration curves. The enzymatic activities were
expressed as pmoles of product/106 cells /h.
4.3. Evaluation of Enzymatic Activities at the Cell Surface of Living Cells
PM-associated activities of total β-glucocerebrosidase, GCase, NLGase, β-galactosidase and
β-hexosaminidase were assessed in living cells, plated in a 96-well microplate at a density of
200,000 cells/well, by a high throughput live cell-based assay as previously described [15,27,31,36].
To distinguish between GCase and NLGase activities, cells were pre-incubated for 30 min at room
temperature in DMEM-F12 without phenol red (Thermo Fisher Scientific, Waltham, MA, USA)
containing 5 nM AMP-DNM or 1 mM CBE, respectively [38]. Total β-glucocerebrosidase assay
was performed using the same procedure without any inhibitors. Activities were assayed using the
artificial substrate MUB-β-Gal for β-galactosidase, MUG for β-hexosaminidase, and MUB-β-Glc for
β-glucocerebrosidases GCase and NLGase. The fluorogenic substrates were solubilized in DMEM-F12
without phenol red at pH 6, with final concentrations of 250 µM, 1 mM, and 6 mM, respectively.
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Aliquots of medium (10 µL) were analyzed at different time points by a Victor microplate reader (Perkin
Elmer, Waltham, MA, USA), after adding 190 µL of 0.25 M glycine, with a pH of 10.7. Standards of free
MUB were used to construct calibration curves. The enzymatic activities were expressed as pmoles of
product/106 cells/h. The experimental design included internal controls. In particular, this method
is based on the observation that the fluorogenic substrates commonly used for the in vitro assay of
glycohydrolytic activities are not taken up by living cells. To assess that the substrate hydrolysis occurs
only upon the activity of PM enzymes, a series of controls was performed. In the used experimental
conditions, we did not observe any intracellular fluorescence, evaluated by both fluorescent microscopy
and fluorimetric analysis of the cells lysed in 0.25 M glycine (pH 10.7), indicating that the substrates
were not able to cross the cell membrane. Moreover, we verified that the artificial substrates did
not undergo either spontaneous or secreted enzyme-driven hydrolysis by the establishment of an
appropriate control without cells or by the solubilization of MUB-substrates directly in cell culture
medium in the presence or not of cells.
4.4. Real-Time PCR
Total RNA was isolated from the LCLs using the RNeasy® Midi kit (Qiagen, Hilden, Germany)
as described in the manufacturer’s instructions. cDNA synthesis was performed using 1µg of total
RNA according to the instructions of the Protoscript® M-MuLV II First Strand cDNA Synthesis Kit
(New England Biolabs, Ipswich, Massachusetts, USA). Real-time PCR was carried out using the
CFX96 Real-Time system (Bio-Rad, Hercules, CA, USA) and the amplification was done using the
SsoFast EvaGreen Supermix according to the manufacturer’s instructions (Bio-Rad, Hercules, CA,
USA). The sequences of the primers are available upon request. GBA1 and GBA2 mRNA expression
levels were normalized to the actin house-keeping gene (ACTB) and relative mRNA expression was
calculated according to the ∆∆CT method.
4.5. Immunoblotting
Equivalent amounts of proteins associated with total cell lysates, determined by DC Protein Assay
(Bio-Rad, Hercules, CA, USA), were separated on polyacrylamide gels and then transferred to PVDF
(Polyvinylidene fluoride) membranes by electroblotting [29]. Blots were incubated with monoclonal
rabbit anti-GCase (ab128879, Abcam, Cambridge, UK) or polyclonal rabbit anti-GAPDH (G9545,
Sigma-Aldrich) primary antibodies at 4 ◦C overnight, followed by incubation with goat anti-rabbit
HRP-conjugated (7074, Cell Signaling) secondary antibody and detection with a chemiluminescent kit
(WESTAR ηC, Cyanagen, Bologna, Italy). Digital images were obtained by the chemiluminescence
system Alliance Mini HD9 (UVItec, Cambridge, UK).
4.6. Cell Sphingolipid Labelling with [1-3H]-Sphingosine
[1-3H]-sphingosine was administered as tracer in non-bioactive concentration for 2 h (pulse)
followed to 96 h (chase), to allow steady state metabolic labelling of all cell SLs [39]. Briefly,
[1-3H]-sphingosine dissolved in methanol was transferred into a sterile glass tube, dried under a
nitrogen stream and then solubilized in an appropriate volume of pre-warmed (37 ◦C) cell culture
medium to obtain a final concentration of 30 nM. The correct solubilization was verified by measuring
the radioactivity associated with an aliquot of the medium using a β-counter (PerkinElmer, Waltham,
MA, USA). After 2 h of incubation (pulse) the medium was removed, and the cells were incubated for
96 h (chase) in fresh culture medium without radioactive sphingosine. After chase, cells were collected,
lyophilized and subjected to lipid extraction and SLs analysis. Total lipids from lyophilized cells
were extracted with chloroform:methanol:water 20:10:1 by volume, followed by a second extraction
with chloroform:methanol: 2:1 by volume. The radioactivity associated with total lipid extract,
was evaluated by liquid scintillation, using a β-counter system (PerkinElmer).
[3H]SLs of total extracts were separated by high performance thin layer chromatography (HPTLC),
using the solvent system chloroform:methanol:water 110:40:6 by volume. [3H]SLs were identified by
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digital autoradiography using TRacer system (Biospace Lab) and quantified with M3vision software.
The lipid identification was performed using purified radioactive standards.
4.7. Lipid Analysis by SFC-MS/MS
Quantitative analysis of glucosylceramide, galactosylceramide, glucosylsphingosine and
galactosylsphingosine was performed by Lipidomics Shared Resources Analytical Unit (Medical
University of South Carolina, Charleston, SC, USA) [40]. Briefly, quantitative analysis of sphingolipids
is based on eight-point calibration curves generated for each target analyte. The synthetic standards,
along with a set of internal standards, were spiked into an artificial matrix and subjected to an identical
extraction procedure as the biological samples. These extracted standards were then analyzed by the
SFC-MS/MS system operating in positive MRM mode employing a gradient elution. Peaks for the
target analytes and internal standards were recorded and processed using the instrument’s software
system. The calibration curve for a particular analyte was generated by plotting the analyte/internal
standard peak area ratio against analyte concentrations. Any sphingolipid for which no standards
were available was quantitated using the calibration curve of its closest counterpart. Separation of
galactosylceramide and glucosylceramide was performed by SFC-MS/MS. The equipment consisted
of a Waters UPC2 system coupled to a Thermo Scientific Quantum Access Max triple quadrupole mass
spectrometer, equipped with an ESI (electrospray ionization) probe operating in the multiple reaction
monitoring positive ion mode tuned and optimized for the Waters UPC2 system. Chromatographic
separations were obtained utilizing carbon dioxide gas and 1 mM ammonium formate in 0.2% formic
acid in the methanol mobile phase.
Analytical results were expressed as pmoles of lipid/mg of total cellular proteins. Data were the
mean of two independent triplicate experiments.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/19/10/
3099/s1.
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